Cullinan Therapeutics, Inc. (CGEM): Total Liabilities
$39.64M
As of 2025-12-31
$42.03M
As of 2026-06-30
+15.0%
3-year compound annual growth
+22.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $39.64M | +25.9% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $31.50M | +4.0% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $30.29M | +16.1% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $26.09M | +120.9% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $11.81M | -17.9% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $14.39M | n/a | 2022-03-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $39.64M | +25.9% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $350.30M | +69.8% |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $628.44M | n/m |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $256.01M | +2.2% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $123.36M | -2.5% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $158.78M | +49.4% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $1.00B | +15.0% |
Compare CGEM, GLUE, RGNX, VOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗